X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs GLENMARK PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA GLENMARK PHARMA DISHMAN PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 25.1 20.6 121.6% View Chart
P/BV x 3.3 3.6 92.7% View Chart
Dividend Yield % 0.7 0.3 228.2%  

Financials

 DISHMAN PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
GLENMARK PHARMA
Mar-18
DISHMAN PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs374930 40.3%   
Low Rs129517 24.9%   
Sales per share (Unadj.) Rs197.8322.6 61.3%  
Earnings per share (Unadj.) Rs21.228.5 74.4%  
Cash flow per share (Unadj.) Rs34.739.2 88.6%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.3 287.6%  
Book value per share (Unadj.) Rs179.9183.0 98.3%  
Shares outstanding (eoy) m80.69282.17 28.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.2 56.7%   
Avg P/E ratio x11.925.4 46.7%  
P/CF ratio (eoy) x7.218.5 39.2%  
Price / Book Value ratio x1.44.0 35.4%  
Dividend payout %9.47.0 134.3%   
Avg Mkt Cap Rs m20,306204,206 9.9%   
No. of employees `0000.813.7 6.0%   
Total wages/salary Rs m5,35518,718 28.6%   
Avg. sales/employee Rs Th19,252.76,636.8 290.1%   
Avg. wages/employee Rs Th6,459.51,364.7 473.3%   
Avg. net profit/employee Rs Th2,064.1586.1 352.2%   
INCOME DATA
Net Sales Rs m15,96191,031 17.5%  
Other income Rs m265914 29.0%   
Total revenues Rs m16,22691,945 17.6%   
Gross profit Rs m4,10316,154 25.4%  
Depreciation Rs m1,0913,019 36.1%   
Interest Rs m9442,856 33.1%   
Profit before tax Rs m2,33411,193 20.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6243,155 19.8%   
Profit after tax Rs m1,7118,039 21.3%  
Gross profit margin %25.717.7 144.9%  
Effective tax rate %26.728.2 94.8%   
Net profit margin %10.78.8 121.4%  
BALANCE SHEET DATA
Current assets Rs m11,01869,887 15.8%   
Current liabilities Rs m9,51732,879 28.9%   
Net working cap to sales %9.440.7 23.1%  
Current ratio x1.22.1 54.5%  
Inventory Days Days11081 135.7%  
Debtors Days Days3593 37.3%  
Net fixed assets Rs m16,30428,892 56.4%   
Share capital Rs m161282 57.2%   
"Free" reserves Rs m12,90751,353 25.1%   
Net worth Rs m14,51651,635 28.1%   
Long term debt Rs m4,18941,418 10.1%   
Total assets Rs m29,805125,954 23.7%  
Interest coverage x3.54.9 70.6%   
Debt to equity ratio x0.30.8 36.0%  
Sales to assets ratio x0.50.7 74.1%   
Return on assets %8.98.6 103.0%  
Return on equity %11.815.6 75.7%  
Return on capital %17.515.1 116.1%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95236,317 13.6%   
Fx outflow Rs m6979,720 7.2%   
Net fx Rs m4,25526,598 16.0%   
CASH FLOW
From Operations Rs m2,78616,481 16.9%  
From Investments Rs m-1,529-10,133 15.1%  
From Financial Activity Rs m-941-4,685 20.1%  
Net Cashflow Rs m3161,770 17.9%  

Share Holding

Indian Promoters % 61.4 48.3 127.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 6.9 53.6%  
FIIs % 12.7 34.4 36.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 10.5 210.5%  
Shareholders   46,261 56,727 81.6%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  PFIZER  ALKEM LABORATORIES  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Recover; Sensex Ends 77 Points Higher(Closing)

Indian share markets witnessed buying interest during closing hours and ended on a positive note. Gains were seen in the metal sector.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 27, 2018 | Updated on Sep 27, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS